Ibalizumab

Specification

• Cat#: THA-0093
• Product Name: Ibalizumab
• Description: Ibalizumab is a CD4-specific antibody used to treat HIV infections.
• Sequences: Not Available
• Molecular Weight: Not Available
• Introduction: Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies. This drug was approved in March 2018 for the management of treatment-resistant HIV. In October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Appearance: Not Available
• Endotoxin Level: < 0.001 EU/μg of the protein by the LAL method

Pharmaceutical Information

• Pharmacodynamics: Trogarzo safety and effectiveness have been confirmed in a clinical trial of 40 patients who suffer multidrug-resistant HIV. The majority of these patients experienced a substantial decrease in their HIV-RNA levels within 7 days after receiving the drug. Approximately 43 percent of patients continued to experience HIV-RNA inhibition after 24 weeks of taking Trogarzo. Trogarzo inhibits viral entry into cells, effectively managing HIV-1 infection in those who have attempted other therapies to no avail.
• Targets: C-C chemokine receptor type 5 C-X-C chemokine receptor type 4 T-cell surface glycoprotein CD4